Endonovo Therapeutics Inc (ENDV)

[brand0nnn]

There was actually an article today I just came upon.

HENDERSON, NV / ACCESSWIRE / July 16, 2018 / When it comes to biotech companies much of the immediate value lies in the speculation. This is because it can take several years for a biotech company to bring their drug or product to market. Considering these facts we have identified Endonovo Therapeutics, Inc. (ENDV) as our breakout stock of 2018.

Endonovo Therapeutics Inc. (ENDV)

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis.

The Company's non-invasive Electroceutical device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company's non-invasive, wearable Electroceuticals work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Most recently Endonovo announced (1) Enrollment of its First Patient in a Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical Therapy, (2) a Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical SofPulse, (3) Highlighted the Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients, and (4) plan to Conduct a Larger Clinical Study to Evaluate Its Electroceutical Therapy in Chronic Kidney Disease.


https://www.marketwatch.com/press-release/3-biotech-stocks-to-bet-on-in-the-second-half-of-2018-2018-07-16